Iilun Murphy, M.D. is the Director for Office of Generic Drugs since June 2023. Dr. Murphy began her FDA career in 2007, joining CDER’s Office of New Drugs, Division of Gastroenterology and Inborn Errors of Metabolism Products as a medical officer. In 2011, Dr. Murphy transitioned to the Center for Tobacco Products serving in various leadership roles within the Office of Science until she returned to CDER in 2020 as the Deputy Director for Clinical and Regulatory Affairs in the Office of Generic Drugs.
Dr. Murphy earned her Bachelor of Arts from Cornell University and her Doctor of Medicine from Stanford University School of Medicine. She completed her pediatric residency through the Harvard University and Boston University Combined Residency Program in Pediatrics and is board certified in pediatric medicine.
Prior to joining the FDA, Dr. Murphy practiced pediatrics in both private office and inpatient hospital settings. She continues her involvement in medical education as an Assistant Clinical Professor of Pediatrics at George Washington University School of Medicine.
